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The role of macroprolactinemia in women with hyperprolactinemia is currently controversial and can
lead to clinical dilemmas, depending upon the origin of macroprolactin, the presence of hyper-
prolactinemic symptoms and monomeric prolactin (PRL) levels. Macroprolactinemia is mostly consid-
ered an extrapituitary phenomenon of mild and asymptomatic hyperprolactinemia associated with
normal concentrations of monomeric PRL and a predominance of macroprolactin conﬁned to the
vascular system, which is biologically inactive. Patients can therefore be reassured that macro-
prolactinemia should be considered a benign clinical condition, resistant to antiprolactinemic drugs, and
that no diagnostic investigations or prolonged follow-up should be necessary. However, a signiﬁcant
proportion of macroprolactinemic patients appears to suffer from hyperprolactinemia-related symptoms
and radiological pituitary ﬁndings commonly associated with true hyperprolactinemia. The symptoms of
hyperprolactinemia are correlated to the levels of monomeric PRL excess, which may be explained as
coincidental, by dissociation of macroprolactin, or by physiological, pharmacological and pathological
causes. The excess of monomeric PRL levels in such cases is of primarily importance and the diagnosis of
macroprolactinemia is misleading or inadequate. However, macroprolactinemia of pituitary origin
associated with radiological ﬁndings of pituitary adenomas may rarely occur with similar hyper-
prolactinemic manifestations, exclusively due to bioactivity of macroprolactin. Therefore, in such cases
with hyperprolactinemic signs and pituitary ﬁndings, macroprolactinemia should be considered a
pathological biochemical condition of hyperprolactinemia. Accordingly, individualized diagnostic in-
vestigations with the introduction of dopamine agonists, or other treatment with prolonged follow-up,
should be mandatory. The review analyses the laboratory and clinical signiﬁcance of macroprolactinemia
in hyperprolactinemic women suggesting clinically useful diagnostic and treatment strategies.
© 2017 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prolactin (PRL) is a globular protein hormone of 199 aminoacids
produced by the anterior pituitary lactotrophic cells that acts with
other hormones to initiate secretion of milk by the mammary
glands. PRL homeostasis is under hypothalamic regulationwith the
primary control of its secretion being inhibitory rather than stim-
ulatory. The hypothalamic factor that chieﬂy inhibits PRL secretionand Gynecology, University
f Medicine, Petrova 13, 10000
Gynecology. Publishing services b
ser (n/a) at University Hospital Zagre
. No other uses without permission. Cat the level of D2 receptors is the neurotransmitter dopamine
which is believed to be the principal PRL inhibiting factor (PIF). The
PRL-releasing factors include vasoactive intestinal peptide,
epidermal growth factor and thyrotrophin-releasing hormone, as
the only important clinical manifestation that occurs with hypo-
thyroidism. Heterogeneity in the molecular size of PRL has been
described in the majority of serum from normal and hyper-
prolactinemic individuals and threemajor variants can be classiﬁed
including monomeric, dimeric and polymeric isoforms. The
monomeric or little PRL (MW 23 kDa) results from a cleaved pre-
prolactin molecule (MW 26 kDa) and it represents the major cir-
culatory isoform (80e95%) of the total PRL in cases with
normoprolactinemia and true hyperprolactinemia. The biologicaly Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
b from ClinicalKey.com by Elsevier on October 29, 2018.
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attributed to the monomeric form [1]. The most common symp-
toms of monomeric PRL excess in premenopausal women are oli-
gomenorrhea/amenorrhea and galactorrhea, which result from the
inhibitory effect on gonadotrophin-releasing hormone (GnRH)
secretion and from the stimulatory effect on the proliferation and
differentiation of mammary cells during lactation. The predomi-
nant physiologic consequence of hyperprolactinemia is hypo-
gonadotrophic hypogonadism due to suppression of pulsatile
GnRH. Furthermore, women with hyperprolactinemia can present
with various other symptoms including; a short luteal phase,
menstrual irregularities, decreased libido or orgasmic dysfunction,
anovulation, infertility, chronic hyperandrogenism due to increased
dehydroepiandrosterone sulfate secretion from the adrenals, pro-
longed hypoestrogenism, decreased bone mass and osteopenia [2].
The most common other forms of PRL with lower biological
activity include the dimeric (big PRL, MW 48e56 kDa) and the
polymeric isoform ormacroprolactin (bigebig PRL, MW> 150 kDa),
that account for less than 10% and 1%, respectively, of the total PRL
levels in normal sera. Macroprolactinemia represents a state of
hyperprolactinemia characterized by the predominance of bigebig
PRL and it is mainly suspected in asymptomatic individuals or those
without the typical hyperprolactinemia-related symptoms. Among
the three most common causes of hyperprolactinemia, in addition
to prolactinomas and neuroleptics/antipsychotic drugs, macro-
prolactinemia can also be included. Although the nature of mac-
roprolactin is heterogenous it is mainly recognized as an
antigeneantibody complex of high stability consisting primarily of
monomeric PRL and immunoglobulin (Ig) G isotype. Furthermore,
in cases with slightly elevated PRL levels, non-IgG-bound forms of
macroprolactin including complexes with IgA or IgM, highly gly-
cosylated monomeric PRL, covalent or noncovalent aggregates of
monomeric PRL, have rarely been demonstrated. Macroprolactin is
conﬁned to the vascular system owing to its high molecular size
and therefore its access to the PRL receptors of target organs in the
periphery and centrally is prevented. Accordingly, the absence of
macroprolactin in extravascular spaces and the pituitary may be
proceeded by the loss of hyperprolactinemia-related symptoms [3].
It seems that asymptomatic macroprolactinemia in women with
hyperprolactinemia might be a stable and long-lasting condition
for up to 10-years [4]. In patients with macroprolactinemia and
normal concentrations of monomeric PRL no symptomatic pro-
gression was noted during a 10-year clinical follow-up, macro-
prolactinemia therefore may be considered a benign variant of
hyperprolactinemia. Such patients have been reassured that no
pituitary imaging investigations and dopamine agonist treatments
were necessary [5]. Consequently, routine diagnostic screening of
all hyperprolactinemic women for macroprolactin has been rec-
ommended as ﬁnancially justiﬁed due to reduced use of imaging
and dopamine agonist treatment in such patients [6]. Although
patients with macroprolactinemia are usually asymptomatic and
have normal menstrual cycles with spontaneous conceptions, there
are a number of women with macroprolactinemia presenting
hyperprolactinemic clinical symptoms due to the rise in the levels
of monomeric PRL, that cannot be differentiated from the patients
with true hyperprolactinemia [7e11]. Since in patients with mac-
roprolactinemia at least one of these symptoms may be found, no
clinical feature can reliably distinguish macroprolactinemic from
true hyperprolactinemic individuals [7]. Unfortunately, no labora-
tory investigations and hyperprolactinemia related symptoms are
useful in differentiating patients with monomeric hyper-
prolactinemia from those individuals with macroprolactinemia [8].
Furthermore, a comparison of different immunoassays for the
detection of macroprolactin in hyperprolactinemic patients
demonstrated no difference in the incidence ofDownloaded for Anonymous User (n/a) at University Hospital Z
For personal use only. No other uses without permissionhyperprolactinemia-related symptoms, including abnormal
menses, galactorrhea, or abnormal pituitary imaging without re-
gard to considering the presence of macroprolactin [9]. Since oli-
gomenorrhea and galactorrhea occur in 57% and 29% of patients
with macroprolactinemia, hyperprolactinemia was a signiﬁcant
cause of frequent misdiagnosis and mismanagement before the
introduction of macroprolactin screening by the use of appropriate
laboratory immunoassays [10]. Consequently, it is essential for
clinical laboratories to introduce screening methods to analyze
blood samples in hyperprolactinemic patients and to determine the
presence of macroprolactin and the monomeric PRL component of
all hyperprolactinemic sera [11]. Although the presence of macro-
prolactinemia is suspected mainly in cases of mild hyper-
prolactinemia without pathological pituitary ﬁndings, a few cases
of macroprolactinemia with prolactinomas and typical hyper-
prolactinemic symptoms have been recently reported. Since the
symptoms of hyperprolactinemia disappeared after treatment with
dopamine agonists, biological activity of the high-molecular iso-
form has been suggested similar to that of elevated monomeric PRL
levels. Consequently, in these rare cases of macroprolactinemia
pituitary diagnostic imaging, medical treatment, and prolonged
follow-up may be required [12]. The review aims to asses the lab-
oratory and clinical signiﬁcance of macroprolactinemia in women
with hyperprolactinemia, and pathophysiologic mechanisms of
macroprolactinemia, suggesting different approaches which may
be useful in diagnostic evaluation and adequate treatment in clin-
ical settings of such patients.
Prevalence
Although the proportion of macroprolactinemia has earlier been
reported less commonly in men (0.02%) than in women (0.2%),
according to more recent data it may be more common with a
general prevalence of 3.7% with no difference between the
sexes [13,14]. However, in hyperprolactinemic populations the
mean proportion of macroprolactinemia is 25% and varies between
15 and 35% [8,12,13]. A higher incidence of macroprolactinemia of
46% reported by a study center which received samples sent from
other laboratories where the possible diagnosis of macro-
prolactinemia was raised, may reﬂect selection bias [15].
Clinical features
According to earlier reports macroprolactinemia appeared in
isolated cases of asymptomatic women or healthy volunteers, with
normal concentration of monomeric PRL and between 85 and 90%
of serum PRL bigebig PRL. Limited bioactivity in vivo without the
symptoms of hyperprolactinemia has been supported by an
explanation that the bigebig PRL complex is conﬁned to the
vasculature due to its high molecular mass preventing its approach
to the target cells [16,17]. Consequently, the new term “macro-
prolactinemia” was used for the ﬁrst time in 1985 for such cases of
hyperprolactinemia whose PRL mainly consisted of bigebig PRL, to
characterize a nonprogressive state and a novel cause of hyper-
prolactinemia [18].
However, later investigations in patients with macro-
prolactinemia revealed a lower incidence of hyperprolactinemia-
related clinical symptoms and abnormal imaging ﬁndings in the
pituitary gland compared with patients exhibiting true hyper-
prolactinemia [5,10,15,19e23]. In a cohort of 51 patients with
macroprolactinemia, headache was present in twelve patients
(24%), oligomenorrhea in ﬁve (10%) and galactorrhea in two cases
(4%), without symptomatic progression during prolonged follow-
up. Therefore, such patients with macroprolactinemia and normal
concentrations of monomeric prolactin can be reassured, andagreb from ClinicalKey.com by Elsevier on October 29, 2018.
. Copyright ©2018. Elsevier Inc. All rights reserved.
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Normal pituitary images were more common in patients with
macroprolactinemia than in patients with monomeric hyper-
prolactinemia (78.9% vs. 25%), whereas hyperprolactinemic symp-
toms were more likely in individuals with true hyperprolactinemia
than in patients with macroprolactinemia (90% vs. 54%) [15]. Since
symptoms typical of hyperprolactinemia were not common in 55
patients withmacroprolactinemia (onewith galactorrhea and eight
with oligomenorrhea), referral and intensive investigation of these
patients was not be suggested [19]. Similarly in a study of 106 pa-
tients with macroprolactinemia, menstrual abnormalities and
galactorrhea occurred less commonly than in women with true
hyperprolactinemia (25% vs. 37% and 12% vs. 34%, respectively)
[20]. Hyperprolactinemia occurred in 15e20% of women with
menstrual disturbances and 30e40% of infertile women, and can
adversely affect fertility. Since the prevalence of oligomenorrhea
and galactorrhea was signiﬁcantly higher in patients with true
hyperprolactinemia than macroprolactinemia (46 vs. 14%, and 30
vs. 5%, respectively), measurement of PRL should be a part of
routine evaluation of couples with infertility [21]. Contrary to
multiple impairments of sexual functions such as sexual desire and
arousal, lubrication, orgasm, sexual satisfaction, and dyspareunia.
With depressive symptoms in women with elevated monomeric
prolactin, it seems that macroprolactinemia only disturbs sexual
desire [22]. Despite lower frequency of galactorrhea and abnormal
pituitary ﬁndings in macroprolactinemic compared to monomeric
hyperprolactinemia (39.2 vs. 57.1% and 65.3 vs. 81.1%, respectively),
macroprolactinemia has been suggested as a pathological
biochemical variant of hyperprolactinemia [23].
Moreover, according to later studies therewere no differences in
typical hyperprolactinemia-related symptoms between patients
with macroprolactinemia and monomeric hyperprolactinemia,
because the symptoms related to PRL excess were reported more
frequently in subjects with macroprolactinemia [7e9,24].
Furthermore, there were no signiﬁcant differences in hormonal
levels such as gonadotrophins, estradiol or testosterone levels be-
tween the groups of patients. Nevertheless, the patients with
macroprolactinemia had a lower infertility rate (6.7% vs. 32.7%) and
a greater percentage of normal pituitary ﬁndings (73.3% vs. 34.5%)
than those with true hyperprolactinemia. Despite the fact that
clinical symptoms and laboratory ﬁndings cannot be used reliably
to distinguish macroprolactinemia from true hyperprolactinemia,
routine laboratory screening for all hyperprolactinemic sera with
PEG might prevent the unnecessary use of radiological techniques
andmedical treatment. Consequently, physicians should encourage
laboratories to make the measurement of macroprolactin in daily
practice for such patients with hyperprolactinemia [24].
Diagnosis
Macroprolactinemia has often been neglected in the differential
diagnosis of hyperprolactinemia, mainly due to the lack of adequate
diagnostic methods and lack of awareness among specialists, and
therefore patients have often undergone unnecessary diagnostic
investigations, treatment and follow-up. Among laboratory tech-
niques gel ﬁltration chromatography (GFC) is known as the gold
standard and represents an accurate and reproducible method.
Since it is an expensive, time-consuming and labor-intensive
technique, clinicians are often discouraged from using it in un-
clear situations of hyperprolactinemia [20]. Although the separa-
tion of macroprolactin by immunoadsorption with Protein A (PA)
and Protein G (PG) offers acceptable precision, pretreatment of sera
with PA and PG may lead to a signiﬁcant overestimation of
monomeric PRL concentrations [25]. Another technique - the
detection of macroprolactin by precipitation and ultraﬁltrationDownloaded for Anonymous User (n/a) at University Hospital Zagre
For personal use only. No other uses without permission. Crepresents a practical alternative to GFC for estimating the mac-
roprolactin, although the PRL levels after ultraﬁltration, may vary
considerably from sample to sample, compared with those after
GFC [26]. However, during recent years precipitation with poly-
ethylene glycol (PEG) has been commonly used to separate the
isoforms of PRL as a simple, cheap, accessible, rapid, reproducible
and the most suitable technique for screening of macroprolactin in
hyperprolactinemic patients [19,27,28]. A concentration of 25% PEG
is added to the same volume of serum and after a short period of
incubation it is centrifuged to precipitate out macroprolactin.
Although it is not necessary to incubate the PEG-treated sample,
the use of cold PEG and vortex mixing are important. Total PRL is
deﬁned as the PRL concentration in the water-treated sample and
free PRL is deﬁned as the PRL concentration in the supernatant after
PEG precipitation. The amount of macroprolactin can be calculated
as follows: (total PRLfree PRL)/total PRL  100 which represents
the PEGeprecipitable PRL (%). It has become accepted that a PEG-
precipitation ratio greater than 60%, or recovery less than 40% af-
ter PEG, is considered the reliable criteria for the diagnosis of
macroprolactinemia. Since precipitation using 5-fold diluted serum
with 25% PEG6000 can effectively reduce macroprolactin concen-
trations by increasing the PRL recovery rate, this represents a new
method for the detection of genuine hyperprolactinemia
[6,9,25,27e29]. Nevertheless, PEG may also induce a partial pre-
cipitation of monomeric PRL (up to 25%) and therefore this method
lacks speciﬁcity, which may result in an underestimation or
misinterpretation of PRL concentrations in cases of macro-
prolactinemia with simultaneously supraphysiological of mono-
meric PRL [9,25,27,30]. Since it has been demonstrated that the
presence of PEG in the sample can interfere with some PRL
immunoassay procedures, it has been recommended that each
laboratory, undertaking macroprolactin screening, should establish
method-speciﬁc reference intervals derived by use of PEG-treated
sera from healthy individuals [9,27,30,31].
Although radiological evaluation of pituitary imaging by
computerized axial tomography (CT) or magnetic resonance im-
aging (MRI) in patients with macroprolactinemia is usually nega-
tive, a few cases of radiographic abnormalities have been recently
reported. The prevalence of macroprolactinemia among newly
diagnosed patients with prolactinoma was similar compared with
the control group of healthy subjects (3.5 vs. 3.7%). The coexistence
of a pituitary adenoma and macroprolactinemia or macroprolactin
production by the pituitary tumor itself has been offered as an
explanation in these rare cases [12].
Pathophysiology
The pathogenesis of macroprolactinemia is mainly thought to be
an extrapituitary, post-secretory phenomenon of anti-PRL autoan-
tibodies, which are conﬁned to the vascular system due to the high
molecular weight of the macroprolactin molecules. The conse-
quence is an asymptomatic state with a typical lack of bioactivity
in vivo due to normal concentrations of monomeric PRL levels and
the inability of macroprolactin to cross the endothelium to access
PRL receptors in the extravascular compartment and centrally.
Moreover, in the presence of anti-PRL antibodies, the renal clear-
ance of PRL is slower which precludes ﬁltration of the bound PRL
ﬁltration from the glomeruli, and therefore macroprolactinemia
results due to the delayed clearance of PRL rather than increased
production. Since these PRL antibodies remain stable during a long-
term follow-up (>10 years), macroprolactinemia may be regarded
as a state of longer duration [3e5,19,29]. Another reason for lower
biological activity of macroprolactin and lack of typical hyper-
prolactinemic symptoms, may be the competitive binding of anti-
PRL autoantibodies to their binding sites (epitopes) on PRLb from ClinicalKey.com by Elsevier on October 29, 2018.
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receptors [32]. In addition, the biological activity of macroprolactin
is dependent upon the bioassay used, because it is considerably
lower toward the homologous receptor-mediated Ba/F-LLP assay,
than in the commonly used heterologous rat Nb2 cell assay [33].
The pathogenesis of PRL antibodies is still controversial because
some autoimmune disorders such as systemic lupus erythematodes
may be accompanied with macroprolactinemia and monomeric
hyperprolactinemia [34], whereas other studies found no evidence
of speciﬁc correlation [20,35]. Furthermore, it may be that envi-
ronmental factors and genetic susceptibility are the potential
mechanisms included in the genesis of anti-PRL autoantibodies,
which may alter the immune response in hosts in a similar manner
like to other autoimmune disorders [36]. However, since pituitary
PRL with some changes in its molecule represents an increased
antigenicity to the immune system it may cause an autoimmune
response resulting in the production of anti-PRL antibodies [37]. It
seems that PRL antibodies represent the cause of mild hyper-
prolactinemia commonly found in patients with hyper-
prolactinemia due to a signiﬁcant positive correlation between
anti-PRL autoantibody titers and slower serum clearance of mac-
roprolactin from the bloodstream. Furthermore, the complex
autoantibody-bound PRL may be a cause for the absence of the
hypothalamic feedback mechanism, because macroprolactin
cannot access the hypothalamus due its higher size. Consequently,
the hormonal concentrations of serum estradiol and luteinizing
hormone (LH) are usually signiﬁcantly higher in patients with
macroprolactinemia than individuals with monomeric hyper-
prolactinemia [10,14,18,38]. Despite the fact that the majority of
patients with macroprolactinemia reﬂect asymptomatic clinical
presentation, hyperprolactinemia-related symptoms commonly
occur mainly due to the rise in the levels of monomeric PRL, similar
to individuals with true hyperprolactinemia [7e11]. In cases with
the supraphysiological concentrations of monomeric PRL, the hy-
pothalamic negative feedback mechanism restores by increasing of
hypothalamic dopaminergic neuronal activity, to normalize
elevated free PRL levels. In addition, the increased concentrations of
monomeric PRL lead to suppression of kisspeptin-1 expression,
secretion of GnRH and gonadotropins, resulting in oligomenorrhea
or amenorrhea and reﬂected as an anovulatory infertility [39]. The
ﬁnal result of gonadotropins suppression is dependent of mono-
meric PRL levels and varies from a short luteal phase to amenorrhea
or hypogonadism. Lower PRL concentrations in patients with mild
hyperprolactinemia (20e50 ng/mL) may cause poor preovulatory
follicular development with a short luteal phase, moderate hyper-
prolactinemia (50e100 ng/mL) usually leads to oligomenorrhea or
amenorrhea, whereas higher PRL levels (>100 ng/mL) frequently
result in profound hypogonadotropic hypogonadism [1]. The
increased levels of monomeric PRL responsible for typical
hyperprolactinemia-related symptoms frequently found in patients
with macroprolactinemia may be coincidental [10], or may be
explained by intermittent dissociation of the macroprolactin
complex in some cases [40]. Furthermore, the simultaneous pres-
ence of macroprolactinemia and increased levels of monomeric
may be found in pregnancy or due to pharmacological or patho-
logical causes such as stress, hypothyroidism, renal and hepatic
failure, intercostal nerve stimulation by trauma or surgery, and
polycystic ovary disease. It is important in these symptomatic pa-
tients with macroprolactinemia to establish the exact pathologic
state and to introduce dopaminergic agonists or other treatment
modalities regardless of the presence of macroprolactin, because
the presence of increased levels of monomeric PRL is of primarily
concern. However, the use of dopamine agonists is not recom-
mended in a macroprolactinemic patient with normal monomeric
PRL levels who should be correctly evaluated for irregular mensesDownloaded for Anonymous User (n/a) at University Hospital Z
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withmacroprolactinemia. Idiopathic hyperprolactinemia should be
considered in cases if all other causes in addition to pituitary
ﬁndings may be excluded [41]. However, similar
hyperprolactinemia-related symptoms occurred in rare cases of
macroprolactinemia associated with prolactinoma. Although mac-
roprolactin has been generally considered as a biologically inactive
molecule, decrease of macroprolactin levels after dopamine treat-
ment suggests pituitary origin and biological activity of the high-
molecular isoform comparable with that of monomeric prolactin
isoform in these rare cases [12]. Since the presence of macro-
prolactinaemia and raised free PRL levels in women with oligo-/
amenorrhoea may be associated with high risk of a micro- or a
macro-pituitary adenoma (36%), therefore pituitary MRI has been
suggested as mandatory in all such cases [42]. An extreme form of
macroprolactinemia and an invasive pituitary macroadenoma has
been reported in a female patient with hypogonadotropic hypo-
gonadism, secondary amenorrhea, mild obesity, hirsutism, head-
ache and blurred vision. The signiﬁcant decrease in macroprolactin
levels and tumor volume in response to dopamine agonist therapy,
instead of transsphenoidal surgery, was suggestive for the pituitary
origin of this isoform. Disappearance of clinical signs with
normalization of gonadotropin levels were arguments in favor of
preserved-macroprolactin bioactivity [43]. Similarly, the recovery
of gigantomastia and macroprolactinemia with cabergoline treat-
ment as an alternative to surgery may be suggestive of the possible
role of macroprolactinemia in the etiology of gigantomastia. Mac-
roprolactinemia may be attributed to pituitary adenoma itself as
well as to breast tissue or may be incidental, although it could not
be identiﬁed because pituitary surgery and histopathological
evaluation were not made [44].
Conclusion
Sincemacroprolactinemia inwomenwith hyperprolactinemia is
determined by the origin of macroprolactin, the presence of
hyperprolactinemia-related symptoms, and monomeric PRL levels,
its role is currently controversial as it may lead to clinical dilemmas.
Macroprolactinemia is mostly considered an extrapituitary phe-
nomenon of mild and asymptomatic hyperprolactinemia with
normal concentrations of monomeric PRL and the predominance of
macroprolactin conﬁned to the vascular system, which is biologi-
cally inactive. In such asymptomatic patients macroprolactinemia
should be considered a benign clinical condition with resistance to
antiprolactinemic drugs and no diagnostic investigations or medi-
cal treatment during prolonged follow-up are required. However, a
signiﬁcant proportion of macroprolactinemic patients suffer from
typical hyperprolactinemia-related symptoms and radiologically
diagnosed pituitary ﬁndings, which are usually associatedwith true
hyperprolactinemia. The symptoms of hyperprolactinemia are
mostly correlated to the levels of monomeric PRL excess, which
may be explained as coincidental, by dissociation of macro-
prolactin, or by physiological, pharmacological or pathological
causes. In addition, higher levels of monomeric PRL may be corre-
lated with severity of the symptoms, which vary from a short luteal
phase to amenorrhea with hypogonadotropic hypogonadism.
However, macroprolactinemia of pituitary origin associated with
pituitary adenomas may rarely occur with typical symptoms of
hyperprolactinemia due to bioactive macroprolactin. In these cases
macroprolactinemia represents a pathological biochemical variant
of hyperprolactinemia. Since macroprolactinemia is a common
cause of hyperprolactinemia and many clinical or laboratory fea-
tures cannot be used reliably to differentiate macroprolactinemia
from true hyperprolactinemia, routine screening for all hyper-
prolactinemic sera with PEG might prevent the unnecessary use ofagreb from ClinicalKey.com by Elsevier on October 29, 2018.
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Fig. 1. Laboratory screening of hyperprolactinemic patients.
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should encourage laboratories to make the measurement of mac-
roprolactin in daily practice for such patients with hyper-
prolactinemia. The presence or absence of free PRL concentrations
in patients with macroprolactinemia is crucial whether further
examinations or treatments with dopamine receptor agonists are
necessary or not. If free PRL concentrations are normal, further
examinations and treatments are not necessary. But they are
required if monomeric PRL levels are elevated. It is important in
these symptomatic patients with macroprolactinemia to establish
the exact pathologic state and to introduce dopaminergic agonists
or other treatment modalities regardless of the presence of mac-
roprolactin, because the presence of increased levels of monomeric
PRL is of primarily concern (Fig. 1).
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